Pharmacogenomics testing for mental health
RPRD’s Psych HealthPGx Panel provides broad and actionable insights to help the clinicians make informed treatment decisions. The results of the test may help in choosing the right medications and the appropriate dose for patients undergoing treatments for certain psychiatric conditions, such as depression, anxiety, obsessive compulsive disorder (OCD), and attention deficit hyperactivity disorder (ADHD). The clinical report that contains the test results also includes additional treatment information for therapeutic areas such as pain management, cancer, and cardiovascular care, strictly based on the guidelines published by Clinical Pharmacogenomics Implementation Consortium (CPIC). Our strictly evidence-based interpretations mean full transparency in how we translate the pharmacogenetic test results into clinically useful interpretations.